Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: A review

Metastatic bone lesions are common among patients with advanced cancers. While chemotherapy and radiotherapy may be prescribed immediately after diagnosis, the majority of severe metastatic bone lesions are treated by reconstructive surgery, which, in some cases, is followed by postoperative radioth...

Descripción completa

Detalles Bibliográficos
Autores principales: Phull, Sunjeev S., Yazdi, Alireza Rahimnejad, Ghert, Michelle, Towler, Mark R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856326/
https://www.ncbi.nlm.nih.gov/pubmed/33552885
http://dx.doi.org/10.1016/j.jbo.2020.100345
_version_ 1783646229995978752
author Phull, Sunjeev S.
Yazdi, Alireza Rahimnejad
Ghert, Michelle
Towler, Mark R.
author_facet Phull, Sunjeev S.
Yazdi, Alireza Rahimnejad
Ghert, Michelle
Towler, Mark R.
author_sort Phull, Sunjeev S.
collection PubMed
description Metastatic bone lesions are common among patients with advanced cancers. While chemotherapy and radiotherapy may be prescribed immediately after diagnosis, the majority of severe metastatic bone lesions are treated by reconstructive surgery, which, in some cases, is followed by postoperative radiotherapy or chemotherapy. However, despite recent advancements in orthopedic surgery, patients undergoing reconstruction still have the risk of developing severe complications such as tumor recurrence and reconstruction failure. This has led to the introduction and evaluation of poly (methyl methacrylate) and inorganic bone cements as local carriers for chemotherapeutic drugs (usually, antineoplastic drugs (ANPDs)). The present work is a critical review of the literature on the potential use of these cements in orthopedic oncology. While several studies have demonstrated the benefits of providing high local drug concentrations while minimizing systemic side effects, only six studies have been conducted to assess the local toxic effect of these drug-loaded cements and they all reported negative effects on healthy bone structure. These findings do not close the door on chemotherapeutic bone cements; rather, they should assist in materials selection when designing future materials for the treatment of metastatic bone disease.
format Online
Article
Text
id pubmed-7856326
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78563262021-02-05 Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: A review Phull, Sunjeev S. Yazdi, Alireza Rahimnejad Ghert, Michelle Towler, Mark R. J Bone Oncol Review Article Metastatic bone lesions are common among patients with advanced cancers. While chemotherapy and radiotherapy may be prescribed immediately after diagnosis, the majority of severe metastatic bone lesions are treated by reconstructive surgery, which, in some cases, is followed by postoperative radiotherapy or chemotherapy. However, despite recent advancements in orthopedic surgery, patients undergoing reconstruction still have the risk of developing severe complications such as tumor recurrence and reconstruction failure. This has led to the introduction and evaluation of poly (methyl methacrylate) and inorganic bone cements as local carriers for chemotherapeutic drugs (usually, antineoplastic drugs (ANPDs)). The present work is a critical review of the literature on the potential use of these cements in orthopedic oncology. While several studies have demonstrated the benefits of providing high local drug concentrations while minimizing systemic side effects, only six studies have been conducted to assess the local toxic effect of these drug-loaded cements and they all reported negative effects on healthy bone structure. These findings do not close the door on chemotherapeutic bone cements; rather, they should assist in materials selection when designing future materials for the treatment of metastatic bone disease. Elsevier 2020-12-16 /pmc/articles/PMC7856326/ /pubmed/33552885 http://dx.doi.org/10.1016/j.jbo.2020.100345 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Phull, Sunjeev S.
Yazdi, Alireza Rahimnejad
Ghert, Michelle
Towler, Mark R.
Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: A review
title Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: A review
title_full Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: A review
title_fullStr Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: A review
title_full_unstemmed Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: A review
title_short Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: A review
title_sort bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: a review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856326/
https://www.ncbi.nlm.nih.gov/pubmed/33552885
http://dx.doi.org/10.1016/j.jbo.2020.100345
work_keys_str_mv AT phullsunjeevs bonecementasalocalchemotherapeuticdrugdeliverycarrierinorthopediconcologyareview
AT yazdialirezarahimnejad bonecementasalocalchemotherapeuticdrugdeliverycarrierinorthopediconcologyareview
AT ghertmichelle bonecementasalocalchemotherapeuticdrugdeliverycarrierinorthopediconcologyareview
AT towlermarkr bonecementasalocalchemotherapeuticdrugdeliverycarrierinorthopediconcologyareview